Company / Depreciation & Amortization
Rani Therapeutics Holdings, Inc. Depreciation & Amortization History
FY2021-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Depreciation & Amortization
$1.0M
FY2025
5-year range
$497.0K / $1.0M
FY2021-FY2025
Trend
+25.1%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Increased from $497,000 to $1M over the past 3 years.
Based on SEC 10-K filings.
$1M in FY2025 with a 3-year CAGR of +27.4%.
Increased from $497,000 to $1M over the past 3 years.
Depreciation & Amortization over time
Growth rates
- 3-Year CAGR
- +27.4%
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Key checks
Key Insights
- 3-year CAGR of +27.4%, indicating consistent growth.
- In FY2025, depreciation & amortization increased 25.1% year-over-year.
Company context
Key Data Points
- Altman Z-Score -1.77 (distress zone, below 1.8 threshold)
- Low earnings quality (accrual-heavy earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Depreciation & AmortizationValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $1.0M | +25.1% |
| FY2024 | $822.0K | +65.4% |
| FY2022 | $497.0K | -15.6% |
| FY2021 | $589.0K | - |
As of FY2025 · SEC 10-K · Updated Jun 28, 2026